1225 WITHDRAWN

Yanfei Guo,X Zhang,Juan Su,Xiang Chen,Cheng Peng
DOI: https://doi.org/10.1016/j.jid.2023.03.1239
IF: 7.59
2023-01-01
Journal of Investigative Dermatology
Abstract:Both autophagy and apoptosis are essential processes participating in cell death and maintain cellular homeostasis.The dysregulation of these two biological processes results in development of diseases including cancers.Therefore, targeting nodes of crosstalk between apoptosis and autophagy is a potential strategy for cancer therapy.Melanoma is the most lethal skin cancer accounting for over 80% of skin cancer deaths.We previously identified tumor necrosis factor receptor-associated factor 6 (TRAF6) was overexpressed in melanoma and involved in the malignant phenotype of melanoma cells.Additionally, TRAF6 promotes the activation of fibroblasts to cancer-associated fibroblasts in melanoma.However, the role of TRAF6 in the autophagy and apoptosis remains unclear.In this study, we found that knockdown of TRAF6 significantly induced both apoptosis and autophagy in melanoma cells.The percentage of apoptotic cells elevated nearly three more times after knocking down of TRAF6.Moreover, lots of autophagosomes were observed in TRAF6-deficient melanoma cells.Then we analyzed the transcriptomics data and found the decrease of autophagy related 16 like 2 (ATG16L2) in TRAF6-deficient melanoma cells.Real-time PCR further verify the alteration.Interestingly, knockdown of ATG16L2 resulted in elevated autophagy and apoptosis in melanoma cells.To investigate the mechanism of TRAF6 in regulating ATG16L2, luciferase assay and chromatin immunoprecipitation were performed.The results confirmed that knockdown of TRAF6 inhibited the abundance of c-Jun in the nucleus, which suppressed the transcription activity of ATG16L2.Next, we found cinchonine, a TRAF6 inhibitor, induced autophagy and apoptosis of melanoma cells.In vitro and in vivo studies suggested that cinchonine suppressed the growth of melanoma.Further mechanism studies indicated that cinchonine inhibited the TRAF6/c-Jun/ATG16L2 signaling pathway.Our results suggest that targeting TRAF6/c-Jun/ATG16L2 axis is a promising strategy for melanoma therapy.
What problem does this paper attempt to address?